The effect of omission of adjuvant radiotherapy after neoadjuvant chemotherapy and breast conserving surgery with a pathologic complete response

被引:5
|
作者
Mandish, Steven F. [1 ]
Gaskins, Jeremy T. [2 ]
Yusuf, Mehran B. [1 ]
Amer, Yomna M. [3 ]
Eldredge-Hindy, Harriet [1 ]
机构
[1] Univ Louisville Hosp, Dept Radiat Oncol, Louisville, KY USA
[2] Univ Louisville, Dept Bioinformat & Biostat, Louisville, KY 40202 USA
[3] Univ Louisville, Sch Med, Louisville, KY 40202 USA
关键词
RADIATION-THERAPY; CANCER; STAGE; IRRADIATION; DISTANCE; OUTCOMES; IMPACT; TRASTUZUMAB; POPULATION; CARCINOMA;
D O I
10.1080/0284186X.2020.1797161
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective(s) Neoadjuvant chemotherapy (NAC) is a standard of care for locally advanced breast cancers. Adjuvant radiotherapy (RT) after NAC is an area of active research. We hypothesize overall survival (OS) is not altered by omitting RT in women with a pathologic complete response (pCR) to NAC after breast conserving survery (BCS). Methods Patients from the National Cancer Database who underwent NAC, BCS, and had a pCR were included. Inflammatory disease, <6 months follow up, and unknown variables were excluded. Descriptive statistics characterized the retained cohort. Logistic regression analyzed the influence of variables on the rate of RT omission. Cox proportional hazard modeling analyzed the influence of prognostic variables on OS. Results Of 5383 women included, 364 (7%) omitted RT. 5-year OS was 94.1% with RT, 93% without. RT omission was most likely in women >70yo (adjusted OR2.4, 95%CI 1.58-3.65,p < .0001;reference 40-49 yo), Hispanic (AOR 1.73, 95%CI 1.19-2.52,p = .0044; reference non-Hispanic), >= 20 miles from treatment facility (20-49 miles; AOR 1.45, 95%CI 1.09-1.93,p = .0109: >50 miles; AOR 2.02, 95%CI 1.42-2.87,p < .0001;reference 0-19 miles), grade 1 (AOR 4.29, 95%CI 2.16-8.51,p < .0001; reference grade 3), and clinical T4 disease (AOR 3.17, 95%CI 1.74-5.79,p = .0002; reference T0/1). Women >= 60yo (60-69: AHR 2.33, 95%CI 1.41-3.83,p = .0009:70+:AHR 2.4, 95%CI 1.24-4.62,p = .0092; reference 40-49) and with N1 and N3 disease (N1: AHR 1.67, 95% CI 2.28-3.24,p = .0034; N3: AHR3.37,95%CI2.01-5.65,p < .0001) showed increased death. Triple-positive (AHR 0.18, 95%CI 0.07-0.43,p = .0002) and HER2+ patients (AHR 0.44, 95%CI 0.30-0.64,p < .0001) had improved OS compared to triple-negative disease. No survival difference was seen with omission of RT (log-rank test:p = .1783; Cox model AHR 1.33, 95%CI 0.76-2.31,p = .3181). Conclusion Women >= 70, of Hispanic origin, living >= 20 miles from treatment facility, and grade 1 disease were more likely to omit RT. HER2+ patients had favorable OS, while older age and N3 disease were negative prognostic factors. Omitting RT after a pCR to NAC and BCS was not found to affect OS.
引用
收藏
页码:1210 / 1217
页数:8
相关论文
共 50 条
  • [1] The Effect of Omission of Adjuvant Radiotherapy after Neoadjuvant Chemotherapy and Breast Conserving Surgery with a Pathologic Complete Response
    Mandish, S.
    Gaskins, J.
    Eldredge-Hindy, H. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E66 - E67
  • [2] Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery
    Tadros, Audree B.
    Yang, Wei T.
    Krishnamurthy, Savitri
    Rauch, Gaiane M.
    Smith, Benjamin D.
    Valero, Vicente
    Black, Dalliah M.
    Lucci, Anthony, Jr.
    Caudle, Abigail S.
    DeSnyder, Sarah M.
    Teshome, Mediget
    Barcenas, Carlos H.
    Miggins, Makesha
    Adrada, Beatriz E.
    Moseley, Tanya
    Hwang, Rosa F.
    Hunt, Kelly K.
    Kuerer, Henry M.
    JAMA SURGERY, 2017, 152 (07) : 665 - 670
  • [3] The safety of breast-conserving surgery in patients who achieve a complete Pathologic response after Neoadjuvant chemotherapy
    Peintinger, Florentia
    Symmans, W. Fraser
    Gonzalez-Angulo, Ana M.
    Boughey, Judy C.
    Buzdar, Aman U.
    Yu, T. Kuan
    Hunt, Kelly K.
    Singletary, S. Eva
    Babiera, Gildy V.
    Lucci, Anthony
    Meric-Bernstam, Funda
    Kuerer, Henry M.
    CANCER, 2006, 107 (06) : 1248 - 1254
  • [4] Local Recurrence According to Whether Pathologic Complete Response has Been Achieved After Neoadjuvant Chemotherapy and Breast Conserving Surgery
    Kook, Yoonwon
    Chu, ChihHao
    Bae, Soong June
    Jang, Ji Soo
    Baek, Seung Ho
    Ahn, Sung Gwe
    Jeong, Joon
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S231 - S232
  • [5] Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy
    Hee Jun Choi
    Jai Min Ryu
    Isaac Kim
    Seok Jin Nam
    Seok Won Kim
    Jonghan Yu
    Jeong Eon Lee
    Se Kyung Lee
    Breast Cancer Research and Treatment, 2019, 176 : 591 - 596
  • [6] Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy
    Choi, Hee Jun
    Ryu, Jai Min
    Kim, Isaac
    Nam, Seok Jin
    Kim, Seok Won
    Yu, Jonghan
    Lee, Jeong Eon
    Lee, Se Kyung
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (03) : 591 - 596
  • [7] Adjuvant chemotherapy in patients with rectal cancer achieving pathologic complete response after neoadjuvant chemoradiation and surgery
    Tomasello, Gianluca
    Ghidini, Michele
    Petrelli, Fausto
    EUROPEAN JOURNAL OF CANCER, 2019, 108 : 97 - 99
  • [8] Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery (vol 152, pg 665, 2017)
    Tadros, A. B.
    Yang, W. T.
    Krishnamurthy, S.
    JAMA SURGERY, 2017, 152 (07) : 708 - 708
  • [9] Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
    Zhu, Jiujun
    Li, Jianbin
    Fan, Zhimin
    Wang, Haibo
    Zhang, Jianguo
    Yin, Yongmei
    Fu, Peifen
    Geng, Cuizhi
    Jin, Feng
    Jiang, Zefei
    Liu, Zhenzhen
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (16)
  • [10] Comment on 'Adjuvant chemotherapy in patients with rectal cancer achieving pathologic complete response after neoadjuvant chemoradiation and surgery'
    Ma, Bin
    Meng, Qingkai
    EUROPEAN JOURNAL OF CANCER, 2019, 112 : 32 - 33